A 2025 meta-analysis in non–small-cell lung cancer (NSCLC) indicates glucocorticoid administration is significantly associated with worse progression-free survival (PFS) and overall survival (OS) for patients on ICIs. World Journal of Applied Medical Sciences, India., v. 2, n. 11, p. 1–3, 2025. DOI: 10.65336/WJAMS.2025.21101. Disponível em: https://wasrpublication.com/index.php/wjams/article/view/176. Acesso em: 23 mar. 2026.